Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Immatics $110 million follow-on offering
We advised Immatics on the offering of shares
Gamida Cell $20 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Solid Biosciences $75 million common stock PIPE offering
The financing is taking place concurrently with the company’s acquisition of AavantiBio
EDAP TMS $23 million follow-on offering
The ADSs are listed on the Nasdaq Global Market
InnoCare Pharma RMB2.9 billion Shanghai IPO
This is the largest A-share listing by an overseas-listed biotechnology company in 2022 so far
Allakos $150 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Medtronic Global Holdings €3.5 billion notes offering
The investment-grade notes were issued in four tranches
Alignment Healthcare $132.75 million secondary offering
The shares are listed on the Nasdaq Global Select Market
Roivant Sciences $400 million at-the-market offering
We advised the company on an SEC-registered at-the-market offering
IDEAYA Biosciences $92 million follow-on offering
The shares are listed on the Nasdaq Global Select Market